Subsequently, trametinib was used to treat an individual with Noonan syndrome caused by a SOS1 variant (SOS1–Noonan syndrome) and CCLA manifesting as protein-losing enteropathy (83). This evidence concerns the gene SOS1 and Protein-losing enteropathy.